-
ESMO International Perspective | Global Lung Cancer Experts Discuss the OptiTROP-Lung04 Study: Sacituzumab Tirumotecan Breaks Through Post-TKI Resistance
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) were among the earliest beneficiaries of precision targeted therapy. However, once tyrosine kinase inhibitor (TKI) resistance develops and disease progression occurs, the choice of subsequent therapy has long posed a major challenge for clinicians worldwide. The emergence of innovative treatments such as antibody–drug conjugates (ADCs) has brought…
-
ESMO Expert Dialogue | From Chinese Innovation to Global Consensus — Landmark Interpretation of TALENTOP and New Horizons in Perioperative Therapy for Liver Cancer
Hepatocellular carcinoma (HCC) remains one of the deadliest malignancies worldwide. Approximately 60–70% of patients are diagnosed at intermediate or advanced stages, making the pursuit of innovative therapeutic strategies that deliver meaningful survival benefit a long-standing global challenge. Against this backdrop, the TALENTOP study, led by Fan Jia, Academician and Principal Investigator from Zhongshan Hospital, Fudan…
-
ESMO Global Perspective | Professor Denis Soulieres: Lessons From the BURAN Trial and the Road Ahead After Immunotherapy Failure in HNSCC
The Phase III BURAN trial, presented at the recent ESMO Congress, evaluated the PI3K inhibitor buparlisib plus paclitaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who had progressed after PD-1/PD-L1 inhibitor therapy. The study failed to demonstrate improvements in progression-free survival (PFS) or overall survival (OS) compared with…
-
ESMO Global Perspective | Professor Arndt Vogel: From First-Line Advanced Disease to the Perioperative Setting—How Immunotherapy Combinations Are Redefining Hepatocellular Carcinoma Care
With the rapid evolution of immunotherapy–targeted therapy combinations, the management of advanced hepatocellular carcinoma (HCC) has entered a new era. Yet for patients with traditionally high-risk features—such as macrovascular invasion or extrahepatic spread—clinical outcomes have historically remained poor, posing a persistent therapeutic challenge.
-
[The Lancet] Professor Yungang Tao: Breaking Two Decades of Stagnation—The NIVOPOST-OP Trial Redefines Postoperative Adjuvant Therapy for High-Risk Head and Neck Squamous Cell Carcinoma
For patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) at high postoperative risk, the standard of adjuvant concurrent chemoradiotherapy (CRT) has remained unchanged since 2004—despite persistent rates of recurrence and metastasis. Recently, the NIVOPOST-OP trial, led by Yungang Tao of Gustave Roussy Cancer Center, was published in The Lancet, delivering the first…
-
Published in The BMJ: Professor Xu Zhang’s Team Conducts the World’s First RCT Demonstrating That the Reliability of Telesurgery Is Non-Inferior to Local Robotic Surgery
On January 28, a landmark study was published in the world-leading medical journal The BMJ. For the first time, a multicenter randomized controlled trial (RCT) has demonstrated that the reliability of urological telesurgery is non-inferior to conventional local robotic surgery.
-
Professor Jiwei Huang: Clinical Challenges and Future Perspectives of Neoadjuvant Therapy in Renal Cell Carcinoma丨Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The conference brought together leading experts and young scholars in the field of urologic oncology, aiming to establish a high-level academic exchange platform and to jointly explore frontier topics and unresolved challenges in the diagnosis and treatment of…
-
From Evidence-Based Medicine to Strategic Sequencing: Rethinking and Breaking Through Whole-Course Immunotherapy in Urothelial Carcinoma
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The conference brought together the emerging backbone of China’s urologic oncology community, aiming to promote standardized and innovative development in the diagnosis and treatment of urologic malignancies through cutting-edge academic discussion and clinical experience sharing.
Connecting Medical Expertise through Media